Cognition Therapeutics (CGTX)
NASDAQ:CGTX
Want to see CGTX full AI Analyst Report?
CGTX Stock Chart & Stats
$1.19
-$0.03(-3.56%)
At close: 4:00 PM EST
$1.19
-$0.03(-3.56%)
Day’s Range― - ―
52-Week Range$0.22 - $3.83
Previous CloseN/A
Volume950.02K
Average Volume (3M)2.91M
Market Cap
$112.59M
Enterprise Value$57.82M
Total Cash (Recent Filing)$37.00M
Total Debt (Recent Filing)$638.00K
Price to Earnings (P/E)―
Beta2.77
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding89,353,775
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-473.96
Enterprise Value/Ebitda-1.72
Forecast
1Y Price Target
$3.00Price Target Upside152.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionA narrower-than-expected net loss and a cash position described as sufficient could support ongoing development activities without immediate need for new financing.
Real-world ExposureExtension of the expanded access program increases real-world exposure to zervimesine among dementia with Lewy bodies patients, potentially strengthening safety and usage data.
Regulatory ClarityPlanned engagement with the FDA's psychiatry division and prior agreement on registrational design parameters could clarify approval expectations and reduce regulatory uncertainty for zervimesine.
Bears Say
Clinical Outcome RiskAnalyst flags risk that negative clinical data could derail development plans and prevent achievement of projected targets for zervimesine.
Partnership And Commercial RiskPotential partnership issues and weak commercial performance are cited as threats that could limit market uptake even if zervimesine secures approval.
Trial DelaysDelays in advancing clinical trials are identified as a key downside that could push back regulatory submissions and slow development momentum.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.22 and its highest was $3.83 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $112.59M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 18 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Mar 26, 2026. The company reported -$0.037 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.041.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 89,353,775 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.037 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -2.703%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (152.10% Upside)
$3.00 (152.10% Upside)
Hedge Fund Trend
Decreased
By 74.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $32.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.01%
12-Months-Change
Fundamentals
Return on Equity
-104.27%
Trailing 12-Months
Asset Growth
60.05%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
CGTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.View all CGTX earnings summariesCGTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(152.10% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
17.43% Insiders
3.95% Mutual Funds
3.28% Other Institutional Investors
72.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---